Innovation and therapeutic focus Novo Nordisk ® hlights first nine months of 2022 Light blue indicates developments in Q3 2022 Further raise innovation bar for Diabetes treatment • Completion of phase 3a trials with QW insulin icodec • Completion of phase 2 trial with CagriSema in T2D • Phase 1 initiated with once-weekly oral semaglutide Develop superior treatment solutions for obesity • Phase 3 initiated with CagriSema in people with obesity Strengthen and progress Rare disease pipeline • Concizumab phase 3 trial completed in people with HA and B with inhibitors and in people without inhibitors • Phase 3a trial initiated with Mim8 in Haemophilia A • Acquisition of Forma Therapeutics mainly within SCD Sales growth of 16% and Operating profit growth of 14% • Sales in International Operations grew by 11% • Sales in the US grew by 21% with 72% of sales coming from products launched since 2015 Gross margin positively impacted by continued productivity gains in Product Supply Free cash flow of DKK 62.5 billion and DKK 41.9 billion returned to shareholders during 9M 2022 hange rates; T2D: Type 2 diabetes; HA: Haemophilia A; HB: Haemophilia B; SCD: Sickle Cell Disease Financials
Download PDF file